RES-010
Obesity and Fatty Liver Disease
Phase 1Active
Key Facts
About Resalis Therapeutics
Resalis Therapeutics is a private, preclinical-stage biotech company pioneering non-coding RNA (ncRNA) therapeutics for metabolic diseases. Its lead program, RES-010, is a disease-modifying therapy for obesity and fatty liver disease, currently in Phase 1 clinical trials. The company leverages deep expertise in ncRNA biology and lipid metabolism to develop treatments that promise durable, fat-selective weight loss, as demonstrated in robust non-human primate studies. Resalis is positioning itself as a key player in the competitive but high-potential obesity and metabolic disorder treatment landscape.
View full company profile